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MethylPCA: a toolkit to control for confounders in
methylome-wide association studies
Wenan Chen1, Guimin Gao1*, Srilaxmi Nerella2, Christina M Hultman3, Patrik KE Magnusson3, Patrick F Sullivan3,4,
Karolina A Aberg2 and Edwin JCG van den Oord2*

Abstract
Background: In methylome-wide association studies (MWAS) there are many possible differences between cases
and controls (e.g. related to life style, diet, and medication use) that may affect the methylome and produce false
positive findings. An effective approach to control for these confounders is to first capture the major sources of
variation in the methylation data and then regress out these components in the association analyses. This approach
is, however, computationally very challenging due to the extremely large number of methylation sites in the
human genome.
Result: We introduce MethylPCA that is specifically designed to control for potential confounders in studies where
the number of methylation sites is extremely large. MethylPCA offers a complete and flexible data analysis including
1) an adaptive method that performs data reduction prior to PCA by empirically combining methylation data of
neighboring sites, 2) an efficient algorithm that performs a principal component analysis (PCA) on the ultra highdimensional data matrix, and 3) association tests. To accomplish this MethylPCA allows for parallel execution of
tasks, uses C++ for CPU and I/O intensive calculations, and stores intermediate results to avoid computing the same
statistics multiple times or keeping results in memory. Through simulations and an analysis of a real whole
methylome MBD-seq study of 1,500 subjects we show that MethylPCA effectively controls for potential
confounders.
Conclusions: MethylPCA provides users a convenient tool to perform MWAS. The software effectively handles the
challenge in memory and speed to perform tasks that would be impossible to accomplish using existing software
when millions of sites are interrogated with the sample sizes required for MWAS.
Keywords: Principal component analysis, Methylome-wide association studies, Eigen-decomposition, Association
test, MBD-seq

Background
Methylation studies are a promising complement to
genetic studies of DNA sequence variation. First, as
methylation is typically associated with transcriptional repression [1,2], it may account for additional variation in
disease susceptibility. Second, methylation studies can
shed a unique light on clinical phenomena [3] such as sex
differences [4,5], genotype environment interactions [6],
and disease course over time [7]. Finally, methylation sites
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are potential new drug targets [8] and have good properties from a translational perspective such as being stable
and enabling cost-effective assays in biosamples that are
relatively easy to collect [9].
Because detailed prior biological knowledge is lacking, it
will be critical to perform methylome-wide association
studies (MWAS) to detect disease relevant sites [10,11].
The most comprehensive approach uses next-generation
sequencing (NGS) to interrogate DNA methylation on a
genome-wide basis after bisulfite conversion of unmethylated cytosines. The single base resolution afforded
by bisulfite sequencing is attractive but currently this approach is not economically feasible for the large sample
sizes required for MWAS [12]. In a cost-effective alternative the genome is fragmented and the methylated

© 2013 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Chen et al. BMC Bioinformatics 2013, 14:74
http://www.biomedcentral.com/1471-2105/14/74

fragments are bound to antibodies [13] (e.g. MeDIP) or
other proteins [14] (e.g. MBD-seq) with high affinity for
methylated DNA. The unmethylated genomic fraction is
washed away, and then only the methylation-enriched portion is sequenced. A final option involves arrays. Examples
are the commercially available Infinium system from
Illumina [15] that interrogates >450,000 loci or genomewide tiling arrays and the 45 million probe array set from
Affymetrix [16] that offers more comprehensive coverage
of the methylome.
In addition to technical factors associated with processing samples, in MWAS there are many possible differences between cases and controls that may affect the
methylome. Examples include differences in life style, diet,
and medication use. As these confounding variables correlate with both the dependent (case–control status) and
independent variable (methylation status) they will cause
spurious associations that are not of direct substantive
interest because they are unrelated to disease processes.
Controlling for confounders in MWAS is critical to avoid
a flood of false positive findings. If measured, such variables can be regressed out. However, the list of potential
confounders is long, only a subset of these variables will
have been measured, and many confounders may simply
be unknown. Statistical methods that first capture the
major sources of variation in the methylation data, and
then regress out these components when performing the
association analyses may provide an effective solution.
However, because of the ultra high dimension of methylation data (e.g. the methylation of DNA cytosine residues
at the carbon 5 position (5meC) occurs in the vast majority
of cases at CpG sites of which already 27 million exist in
the human reference genome), standard statistical packages or existing software for the analysis of large scale
methylation data cannot be used [17-20]. To address the
computational challenges we developed a toolkit called
MethylPCA that is specifically designed to control for
confounders in MWAS.
MethylPCA uses principal component analysis (PCA) to
capture the major sources of variation in the methylation
data. Although other options exist, PCA has the advantage
of being well developed (e.g. algorithms exist that enable
PCA on ultra-high dimensional data), is computationally
efficient, and has already been successfully applied
to high-dimensional biological data [21]. EIGENSOFT
[21,22] also performs PCA. However, 1) MethylPCA provides an adaptive procedure designed to combine methylation data of neighboring sites into larger blocks prior to
PCA; 2) Even after this data reduction step, calculation of
the input matrix for the PCA would be prohibitive in
terms of memory and CPU time for large sample sizes.
MethylPCA allows partitioning the data into a userspecified number of sets to compute sub-matrices in parallel on a cluster and then assemble those to obtain the
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complete input matrix; 3) To enable a complete and flexible data analysis pipeline, MethylPCA provides options
to perform PCA based on the covariance matrix and/or correlation matrix and includes an association testing procedure
where covariates such as the calculated principal component
scores (PCs) can be regressed out; 4) EIGENSOFT is
designed to process categorical SNP data while our software
can work on the quantitative methylation data.

Implementation
The design philosophy of MethylPCA is to build small
independent executable components first and then combine them to perform complex tasks. There are two advantages for this design style: 1) Easy to debug. Each
component can be debugged independently. 2) Flexible
to use. Each component can be used either independently or combined together. MethylPCA consists of
three major components that can be run individually or
as a pipeline:
1) Creating blocks. This procedure adaptively combines
inter-correlated methylation data from adjacent sites.
2) PCA. It performs PCA on the methylation data and
outputs the calculated PC scores, eigenvalues and
loadings.
3) Association test. It performs association tests using
multiple linear regression with optional supplied
covariates (e.g., age, gender) and the PC scores
calculated from the PCA procedure. It outputs the
test statistics and p-values, as well as a QQ plot.
A user-friendly interface is provided in the form of a
parameter file that controls which and how procedures
are performed (see Additional file 1 for detailed description of software). For example, the above three procedures can be performed sequentially or individually by
putting the parameters corresponding to the procedures
in the parameter file. Each procedure has multiple parameters to be set in the parameter file in order to run it
properly. The computational and I/O intensive parts of
MethylPCA are implemented in C++ and the remainder
in the R language.
Creating blocks

In MWAS correlations often exist between adjacent sites.
Rather than using a sliding window of arbitrary length,
MethylPCA uses an adaptive algorithm that combines
methylation data based on the observed inter-correlations.
A benefit of creating “blocks” is that the data reduction
speeds up subsequent analyses, e.g. the PCA procedure.
The use of blocks may also prevent that the results of
PCA are dominated by a limited number of regions
containing highly correlated sites as well as improve the
signal to noise ratio because a sum of substantially inter-
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correlated measurements is known to be more reliable
than the individual measurements separately [23]. Because
there may be regions in a chromosome where there is differential methylation in just one CpG site, sites that are
uncorrelated with neighboring sites are also kept by
forming “blocks” that consist of a single CpG sites only.
Correlations between sites can occur for different reasons. For example in MBD-seq neighboring CpGs will
be highly correlated because they are largely covered by
the same DNA fragments. Correlations can also occur
because of biological phenomenon [24]. To account for
these different causes, MethylPCA allows creating blocks
in two stages. The first stage combines the sites that are
largely covered by the same fragments to form the level
1 block data. Next the level 1 block data is combined to
capture the “biological” correlations to form the level 2
block data.
Sometimes excluding some sites in the analysis is useful, e.g. those sites with low coverage or that are in repeats. There is an option to provide files that specify
which sites are included or excluded. The computing
time for creating blocks is approximately proportional to
n × p, where n is the number of subjects and p is the
number of sites. Because a block merged from multiple
sites is processed as a single unit in the following analysis, the word “site” in the following text may either
refer to a single CpG site, or a block containing multiple
neighboring CpG sites.
Three parameters control the block creation. The first
is a threshold for the average correlations inside a block
denoted by t1. The second is a threshold denoted by nt
for the number of new sites added to the block that have
a mean correlation with sites already in the block below
a third threshold labeled t2. The merging process of a
block stops if 1) the average correlations in the block is
below t1 or nt new sites are merged having correlations
with sites already in the block below t2. The output
block data uses the mean of all methylation values inside
the block to represent each block and stores the related
block information such as the beginning of the block,
the end of the block and the average correlation within
the block in a separate file.
Principal component analysis (PCA) when p >> n

PCA is typically performed on the p × p sample covari1
ance matrix C ¼ n"1
X T X , where X is the n × p data
matrix, n the number of subjects and p the number of
methylation sites. When p is much larger than n, direct
eigen-decomposition of C is no longer computationally
feasible. However, we can obtain the same PCA results
through eigen-decomposition of the much smaller n × n
1
matrix M ¼ n"1
XX T , sometimes called principal coordinate analysis [25].
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We assume that X has been centered by subtracting
the mean of each column from the original observations.
1
X T X is a p × p
The sample covariance matrix C ¼ n"1
matrix. Suppose λ1, λ2, . . ., λr are the positive eigenvalues in descending order and v1, v2, . . . vr are the corresponding orthonormal eigenvectors of C, with
subscript r being the rank of X. Then PCi = Xvi is the ndimensional column vector of the ith principle component (PC) scores of methylation data across p sites for
all n subjects, where the elements in vi are also called
the loadings of PCi. When p >> n it can be computationally infeasible to conduct the PCA through eigendecomposition of matrix C. Instead, we can calculate
1
PCi by using the n × n matrix M ¼ n"1
XX T , which is a
similarity matrix or inner product matrix between all
subjects. Suppose α1, α2, . . ., αr are the positive eigenvalues in descending order and u1, u2, . . .ur are the corresponding orthonormal eigenvectors of M. Let U = [u1,
u2, . . .ur] and V = [v1, v2, . . . vr]. If U and V are properly
chosen when they are not unique, we have (see[25])
λi ¼ αi

ð1Þ

pffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
PCi ¼ X vi ¼ ui ðn " 1Þαi ; i ¼ 1; . . . ; r:

ð2Þ

So the PC scores can be calculated using ui and αi.
Similarly we have
1
1
vi ¼ pffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi X T ui ¼
X T PCi ; i
ð
n
"
1Þαi
ðn " 1Þαi
¼ 1; . . . ; r;

ð3Þ

Therefore, the loadings vi can also be calculated from
ui and αi. EIGENSOFT [21] employs a similar method to
calculate principle components.
In MethylPCA, we compute and store the n × n matrix
X, and the PCs are then calculated from the eigenvectors
1
of M ¼ n"1
XX T (see Equation 2). The loadings are calculated based on the original data matrix X and the PCs or
the eigenvectors of M (see Equation 3). The main computing challenge (both in memory and time) is the calculation
of the matrix XXT that becomes prohibitive for large samples using existing software. To handle this challenge,
MethlPCA can calculate user-specified chunks of the
matrix XXT after which the full matrix XXT is assembled.
Because each computing job only works on a specified
number of samples loaded into the memory for calculation instead of loading the entire methylation data, this
solves the problem of processing large data sets with limited memory. If a cluster is available, each computing job
can be executed in parallel to speed up the process. Statistics that are used repeatedly (e.g. means of all sites in the
entire sample) are calculated only once and stored to further increase efficiency. PCA based on the correlation
matrix is sometimes preferred because PCA on a
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covariance matrix can be dominated by variables with
large variances [26]. MethylPCA provides options to perform PCA based on the correlation matrix or covariance
matrix. Even though it is possible to calculate the loadings
for each PC, usually we are only interested in the loadings
corresponding to the top PC scores. To reduce the computing time, users can specify the number of top principal
components for which loadings will be calculated. The
computing time of PCs is proportional to n2 × p plus the
time reading the data into the memory. The computing
time for one loading is approximately proportional to n × p.
Because covariates that have been measured can be
regressed out directly in the MWAS, the motivation for
using PCA is typically to control for the unmeasured
confounders. To better capture unmeasured confounders and include those together with the measured covariates in the MWAS, it is possible to regress out
measured covariates prior to performing the PCA. This
could include, for example, technical factors associated
with processing samples such as the quantity of genomic
DNA starting material or sample batches. This option is
implemented using the multiple regression functions
from GNU Scientific Library (GSL) [27]. The adjusted
methylation data used in the PCA are the residuals after
regressing out the measured covariates.
Association test

To enable a complete data analysis pipeline, we also added
the possibility to perform MWAS in MethylPCA through
multiple linear regression analysis using functions in GSL
[27]. It tests the association between the phenotype and
each methylation site while adjusting for covariates. Users
can choose which covariates will be included in the association tests, such as age, gender and PCs. The test statistic
and the p-values for each site are calculated and stored.
Once all test statistics are generated, the genomic control
inflation factor lambda is calculated, which is defined as
the observed median test statistic value divided by the
expected median of a chi-square distribution with 1 degree of freedom [28]. Under the null hypothesis that there
is no effect for any site, lambda is close to 1. Finally a QQ
(quantile-quantile) plot is produced based on the p-values
and the calculated lambda is also displayed. The association tests for different chromosomes can be computed in
parallel to decrease CPU time.
Support for both a single computer and a cluster

An option is provided in the parameter file that controls
whether to submit the computing jobs to a cluster or run it
sequentially on a single computer. After analyzing the parameter file, all computing jobs will be arranged. Each computing job is written as a line of an executable command
with corresponding parameters and is stored into batch
files. For example, the block creating procedure can be
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performed per chromosome, with each command line processing one chromosome in the corresponding batch file.

Results
Simulation study

In this simulation study, we illustrate the effectiveness
of PCA in correcting confounding factors in the association test. We simulate two types of confounding
factors: continuous and dichotomous. We assume that
the same number of cases and controls are collected
in the case–control data and let yi denote the disease
status of the ith subject, 1 for case and 0 for control,
i = 1, . . ., n. We simulate K confounding factors. The
kth confounding factor for subject i as a continuous
variable is simulated as follows:
Fik ¼ bk % yi þ mik ; i ¼ 1; . . . ; n; 1≤k≤K ;
where mik follows a normal distribution with mean 0
and variance σ2, bk is a parameter which together with
σ2 controls the correlation between the kth factor and
the case–control status yi (see Additional file 2). If
the kth confounding factor is dichotomous, such as
smoking/non-smoking status, the distribution of the
confounding factor is simulated as:
PrðFik ¼ 1jyi ¼ 1Þ ¼ p1 ; PrðFik ¼ 1jyi ¼ 0Þ ¼ p2;
i ¼ 1; . . . ; n; 1≤k≤K ;
where p1 and p2 control the correlation between the kth
factor and the case–control status yi (see Additional file
2). The inclusion of the case–control status in the above
models makes sure that there are correlations between
the outcome and the confounding factors.
Next, we introduce correlations between the
confounding factor and the methylation levels. First
we sample the number of CpG sites in each of the 22
chromosomes from a Poisson distribution with the
mean of 4,000. Let xij be the methylation level of the
ith subject on the jth CpG site, then it is simulated
using the following formula:
xij ¼ aj þ

XK

F l
k¼1 ik kj

þ eij ; i ¼ 1; . . . ; n; j ¼ 1; . . . ; J;

k ¼ 1; . . . ; K
where aj is the base level for site j. eij is the normally
distributed error with mean 0 and variance δ2, J is
the total number of CpG sites. lkj is 0 or 1 defining
the influence range of each confounding factor. If lkj
= 1, then the kth confounding factor has effects on
site j, otherwise there is no effect. We set the influence range of the kth confounding factor to cover all
sites of three chromosomes, from chromosome
(k-1) × 2 + 1 to chromosome (k-1) × 2 + 3. This means
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that each factor influences 3 chromosomes and there
is one overlapped chromosome influenced by two factors. To ensure non-negative methylation levels, all
levels are subtracted by the smallest value in the data
matrix X.
500 cases and 500 controls were simulated in each data
set with 5 confounding factors. We did six simulations in
which different combinations of continuous and dichotomous confounding factors were used (see Table 1). We
set bk = 4 and σ = 10 for continuous factors so that the correlation between the continuous confounding factor and
the case–control status was about 0.2. We set p1 = 0.6 and
p2 = 0.4 so that the correlation between the dichotomous
confounding factor and the case–control status was also
0.2. aj were uniformly sampled from 0 to 100. δ was set to
40. We applied MethylPCA on the simulated data sets
and extracted the top PCs after examining the Scree plot,
i.e., plot of eigenvalues. For comparison, we performed association tests with and without the top PCs.
Figure 1 shows the Scree plot of the top 10 eigenvalues
of the data set with 3 continuous confounding factors and
2 dichotomous confounding factors. This plot clearly captures the number of factors. Therefore the top 5 PCs are
included in the following association test. Figure 2 shows
the QQ plot of association tests of the same data set with
and without incorporating the top PCs. It can be seen that
after applying PCs into the testing model, the distribution
of p-values is consistent with the null model. Results of
other simulations have the similar pattern. Table 1 shows
the comparison of lambda values under different simulation settings. We can see that, after regressing out PCs,
the lambda is restored to be very close to 1. This indicated
that MethylPCA controlled for confounders well.
MBD-seq MWAS in 1,500 samples

This study includes 750 schizophrenia cases and 750
controls, as well as 75 technical duplicates. For a detailed
description of this study and the data analysis pipeline see
[29]. In summary, this study is part of a large ongoing project entitled “A Large-Scale Schizophrenia Association
Study in Sweden”. The project is supported by grants from
NIMH and the Stanley Foundation and aims at improving
our understanding of the etiology of schizophrenia and bipolar disorder plus their clinical and epidemiological correlations using high dimensional biological investigations
and proper analysis. For details on the project see [30-32].
Cases with schizophrenia were identified via the Hospital

Figure 1 Scree test on a simulated data set with the top
10 eigenvalues.

Discharge Register. Population controls, who had never
received a discharge diagnosis of schizophrenia, were selected at random from the national population registers
and then group matched to the cases in terms of age,
gender and county of residence. All procedures were approved by ethical committees in Sweden and in the US,
and all subjects provided written informed consent (or
legal guardian consent and subject assent). DNA was
extracted from peripheral donated blood at the local medical facilities of the participants.
We obtained, on average, 68.0 million 50 bp reads per
sample of which 70.8% could be mapped. After several
QC steps we estimated the methylation status of about
27 million autosomal CpGs (all CpGs in the reference
genome hg19/ GRCh37). We eliminated 10,483,766
CpGs (mostly located in repeats) showing alignment
problems according to an in silico alignment experiment
plus another 2,735,400 sites showing low read coverage.
MethylPCA performed data reduction in two stages. The
first stage consists of combining CpG sites that are very
highly correlated (r >0.9) because they are largely covered
by the same 100–200 bp fragments. In the second stage,
we combine the “blocks” from the first stage that are highly
correlated (r > 0.6) typically due to biological processes.
MethylPCA could combine the remaining 15,558,200
CpGs after QC into 8,822,240 stage (level) 1 blocks,

Table 1 The comparison of the genomic control inflation factor of association tests with and without top PCs
Association test
without PCs†
‡

with PCs
*

0c + 5d*

1c + 4d

2c + 3d

3c + 2d

4c + 1d

5c + 0d

2.962

3.199

2.979

2.987

2.873

2.949

1.006

1.008

1.009

1.004

1.009

0.996

The number of continuous confounding factors (followed with c) and the number of dichotomous confounding factors (followed with d) in the simulated data
set. †The association test without incorporating the top PCs as covariates. ‡The association test incorporating the top PCs as covariates.
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Figure 2 QQ plot and the lambda values of the association tests before PCA and after PCA on a simulated data set. Figure 2 (a) shows
the QQ plot and lambda without including PCs in the association test. Figure 2 (b) shows the QQ plot and lambda including PCs in the
association test.

which in turn could be combined into 5,074,538 stage
(level) 2 blocks. This represented a 67.3% data reduction.
The stage 1 blocks were small (15.6 bp) with high intercorrelations (mean r = 0.95) indicating that they involved
CpGs in close proximity that were largely covered by the
same 100–200 bp fragments. The stage 2 blocks comprised an average of 3.1 CpGs with the largest blocks

Figure 3 Scree test from the PCA on the on the MBD-seq data set.

consisting of >18 CpGs and spanning over 500 bp. This
suggested regions seemed to be similarly methylated due
to biological processes.
We performed analyses on the 5,074,538 stage 2 blocks.
To eliminate possible artifacts related to the lab technical
aspects of the data, MethylPCA regressed out 5 technical
factors prior to performing PCA: amount of starting

Chen et al. BMC Bioinformatics 2013, 14:74
http://www.biomedcentral.com/1471-2105/14/74

Page 7 of 9

Figure 4 QQ plot and lambda of the methylome-wide association tests before PCA and after PCA on the schizophrenia data set. (a)
shows the QQ plot and lambda without including PCs in the association test. (b) shows the QQ plot and lambda including PCs in the
association test.

material, amount of DNA captured, the duplication status,
re-run status and the batch number. Based on a Scree test
shown in Figure 3, we choose the top 7 PCs. Age and gender are also included as covariates in the association test.
Figure 4 shows the QQ plot and lambda without and with
PCs as covariates. The results suggested many confounders

(lambda = 7.32) that were subsequently effectively dealt
with by regressing out the selected PCs (lambda =1.12). In
contrast to the simulated data, the empirical data lambda
remained slightly larger than 1. This may be because of disease related cases control differences which need further
investigation. The Manhattan plot in Figure 5 indeed

Figure 5 Manhattan plot for MWAS results on the on the schizophrenia data set. The red line is q value < 0.01 and blue q values < 0.1.
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suggested a considerable number of effects with 141 blocks
being significant when the False Discovery Rate (FDR)
is controlled at the 0.01 level, and 25 blocks passing the
highly conservative Bonferroni correction (threshold = 1.15
× 10-8). The best p-values were 10-11 to 10-10. The top findings were replicated in independent samples using a different technology (targeted bisulfite pyrosequencing) and are
discussed in detail elsewhere [Aberg et al. submitted].
The computations were performed on a cluster. Processing the chromosomes in parallel, it took about 14 hours to create the stage 1 blocks and 4 hours to create
the stage 2 blocks. We regressed out technical factors
prior to the PCA, which took about 2 hours. The PCA
was performed by portioning the similarity matrix into
chunks of 350 subjects. Using 16 processors of 16 Gb
each, the PCA took about 26 hours. The MWAS association test took about 2 hours.

Discussion
A wide variety of other existing methods can in principle
be used to analyze MWAS data. For example, surrogate
variable analysis (SVR) developed in the context of
microarray experiments [33] can be used to identify and
remove unknown latent noise, such as batch effects.
However, direct application of these packages [33], may
not be practical because of the ultra high dimension of
methylation data. Instead, efficient analysis of MWAS
data is likely to require tailored computational tools that
employs parallel computing, uses a low level programming language for CPU intensive calculations, stores
intermediate results to avoid computing the same statistics multiple times or storing results in memory, and
uses algorithms specifically designed for high dimensional data.
Our empirical data showed that the risk of false positives in MWAS is very high, likely because of the many
differences between cases and controls (e.g. life style, diet,
medication use) that affect the methylome. This stressed
the need of controlling confounders for which the package
MethylPCA was designed. It seems reasonable to assume
that if confounders have such pervasive effects on the
methylome, the pathogenic processes that cause the disease may also involve many methylation sites. A careful
inspection of the PCs (e.g. using the loadings generated by
MethylPCA) is important to prevent that disease processes are being regressed out in the MWAS.
As the input methylation data are quantitative values for
a set of genomic locations, MethylPCA can be applied to
methylation data generated by any assay. Furthermore, because the PCA components can be run independently, in
principle it can also be applied to other ultra high dimensional data, such as genome-wide sequence data as long as
the specific input format is followed.
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Conclusions
Controlling for confounders in MWAS presents a major
computational challenge because of the very large number
of possible methylation sites. In this article we introduced
MethylPCA that is specifically designed to handle this
problem. We tested and demonstrated MethylPCA using
simulations and empirical MWAS data from 1,500 subjects. Results showed that MethylPCA effectively controlled for possible confounders.
Availability and requirements
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